- Home
- QFIN vs SLNO Comparison
QFIN vs SLNO Comparison
Compare QFIN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- SLNO
- Stock Information
- Founded
- QFIN 2016
- SLNO 1999
- Country
- QFIN China
- SLNO United States
- Employees
- QFIN N/A
- SLNO 133
- Industry
- QFIN Finance: Consumer Services
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- QFIN Finance
- SLNO Health Care
- Exchange
- QFIN Nasdaq
- SLNO Nasdaq
- Market Cap
- QFIN 3.4B
- SLNO 3.7B
- IPO Year
- QFIN 2018
- SLNO 2014
- Fundamental
- Price
- QFIN $23.66
- SLNO $68.83
- Analyst Decision
- QFIN Strong Buy
- SLNO Strong Buy
- Analyst Count
- QFIN 2
- SLNO 9
- Target Price
- QFIN $45.10
- SLNO $116.78
- AVG Volume (30 Days)
- QFIN 2.0M
- SLNO 1.3M
- Earning Date
- QFIN 11-18-2025
- SLNO 11-04-2025
- Dividend Yield
- QFIN 7.14%
- SLNO N/A
- EPS Growth
- QFIN 68.82
- SLNO N/A
- EPS
- QFIN 7.06
- SLNO N/A
- Revenue
- QFIN $2,618,582,596.00
- SLNO $32,656,999.00
- Revenue This Year
- QFIN $17.10
- SLNO N/A
- Revenue Next Year
- QFIN $6.28
- SLNO $181.30
- P/E Ratio
- QFIN $3.01
- SLNO N/A
- Revenue Growth
- QFIN 9.77
- SLNO N/A
- 52 Week Low
- QFIN $20.45
- SLNO $41.50
- 52 Week High
- QFIN $48.94
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- QFIN 39.43
- SLNO 56.14
- Support Level
- QFIN $20.67
- SLNO $66.12
- Resistance Level
- QFIN $27.59
- SLNO $72.55
- Average True Range (ATR)
- QFIN 1.24
- SLNO 3.32
- MACD
- QFIN -0.31
- SLNO 0.57
- Stochastic Oscillator
- QFIN 44.92
- SLNO 58.93
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.